Expert Lance Sloan, MD, discusses CATALYST trial findings on mifepristone, glucagon-like peptide-1 receptor agonist (GLP-1 RA) resistance, and screening for hypercortisolism in uncontrolled type 2 diabetes (T2D).
Lance Sloan, MD, MSE, FACE, FASN, FACP, FEAA, FASPC
Advertisement
Articles by Lance Sloan, MD, MSE, FACE, FASN, FACP, FEAA, FASPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
5